Calvet, Xavier
Casellas, Fransesc
Saldaña, Roberto
Carpio, Daniel
Mínguez, Miguel
Vera, Isabel
Marín, Laura
Juliá, Berta
,
Funding for this research was provided by:
Merck Sharp & Dohme Spain
Article History
Accepted: 12 February 2021
First Online: 12 March 2021
Declarations
:
: This study was funded by Merck Sharp & Dohme Spain, a subsidiary of Merck & Co. Inc., Kenilworth, NJ, USA.
: Xavier Calvet has served as a speaker, a consultant, and an advisory member for or has received research funding from MSD, Abbvie, Pfizer, Kern Pharma, Takeda, Janssen, Ferring, Faes Farma, Shire Pharmaceuticals, Tillotts Pharma, Otsuka Pharmaceutical, and Vifor Pharma. Francesc Casellas has served as a speaker, a consultant, and an advisory member for or has received research funding from Merck Sharp & Dohme, Abbvie, Pfizer, Takeda, Janssen, Ferring, Faes Farma, Shire Pharmaceuticals, Tillotts Pharma, and Ferrer. Daniel Carpio has served as a speaker, a consultant, and an advisory member for or has received research funding from Merck Sharp & Dohme, Abbvie, Kern Pharma, Takeda, Janssen, Ferring, Shire Pharmaceuticals, Tillotts Pharma, Dr Falk Pharma, and Gebro Pharma. Berta Juliá is an employee of Merck Sharp & Dohme, Spain. Roberto Saldaña, Miguel Mínguez, Isabel Vera, and Laura Marín have no conflicts of interest that are directly relevant to the content of this article.
: The study complied with the Good Clinical Practice standards and the principles of the latest version of the Helsinki Declaration (Brazil, 2013) and was approved by the Parc Taulí Ethics Committee on 27 July, 2017 (approval number: 2017615).
: Confidentiality and anonymity were guaranteed in accordance with the Spanish Law 15/1999 on personal data protection and all participants in the study gave their informed consent.
: Not applicable.
: The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request.
: Not applicable.
: XC, study concept and protocol development, manuscript writing, manuscript review; FC, study concept and protocol development, manuscript review; RS study concept and protocol development, manuscript review; DC, study concept and protocol development, manuscript review; MM, study concept and protocol development, manuscript review; IV, study concept and protocol development, manuscript review; LM, study concept and protocol development, manuscript review; BJ, study concept and protocol development, manuscript writing, manuscript review.